Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort.

•Health services must ready themselves to provide DMTs for people with progressive MS.•Estimated eligibility rates are helpful to plan resource requirements.•Many prevalent cases of progressive MS will require clinical and radiological re-evaluation.•The cost of DMT provision will include both drug and service components.